Getinge AB (publ) (GNGBY) Q2 2026 Earnings Call Transcript

Hi, everyone, and welcome to today's conference. This is Mattias Perjos, the CEO of Getinge. And with me today, I have our CFO, Agneta Palmer. So in today's conference, we'll go through our performance and some of the highlights from the second quarter before we open up for a Q&A. So we can move over to Page #2, please. And as usual, let's start by looking at the development of our strategic KPIs. We continue to clearly track in line with plan to increase the share of sales from recurring revenue, accelerating the share of sales from high-margin products like, for example, our ECLS offering, consumables and infection control and BetaBags in Sterile Transfer. This is all supported by solid and effective quality processes. And sales from recurring revenue continue to make up about two-thirds and the high-margin products are now at 70%. For quality, the number of field actions in relation to sales has decreased significantly, and we're pacing a lot better than last year. These improvements should, of course, be achieved through responsible leverage and also an attractive long-term return on invested capital. With that, we can move over to Page #3, please. So if we zoom in on the second quarter and some of the financial key takeaways for the quarter. Overall, we delivered a healthy financial performance in the quarter with solid top line